The need for cytoprotection

被引：16

作者：

Bukowski, RM

机构：

[1] Experimental Therapeutics Program, The Cleveland Clinic Foundation, Department of Hematology/Oncology, Cleveland, OH 44195-5237

来源：

EUROPEAN JOURNAL OF CANCER | 1996年 / 32A卷

关键词：

cytoprotection; amifostine; cancer;

D O I：

10.1016/S0959-8049(96)00329-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The toxicity associated with chemotherapy is significant and dose limiting. Multiple organ systems can be affected, with both acute and chronic side effects producing adverse effects. The concept of cytoprotection, or the selective protection of normal. tissues is a strategy now being investigated in preclinical and clinical models. Systemic approaches have included the use of compounds such as sodium thiosulphate, diethyldithiocarbamate and amifostine, The most promising results have been obtained with the organic thiophosphate compound amifostine (Ethyol(R), WR-2721). Copyright (C) 1996 Elsevier Science Ltd

引用

页码：S2 / S4

页数：3

共 28 条

[1] MODIFICATION OF CISPLATIN TOXICITY WITH DIETHYLDITHIOCARBAMATE [J].

BERRY, JM ;

JACOBS, C ;

SIKIC, B ;

HALSEY, J ;

BORCH, RF .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1585-1590

[2] CARBOPLATIN COMBINED WITH AMIFOSTINE, A BONE-MARROW PROTECTANT, IN THE TREATMENT OF NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II STUDY [J].

BETTICHER, DC ;

ANDERSON, H ;

RANSON, M ;

MEELY, K ;

OSTER, W ;

THATCHER, N .

BRITISH JOURNAL OF CANCER, 1995, 72 (06) :1551-1555

[3] PHASE-I STUDY OF WR-2721 AND CARBOPLATIN [J].

BUDD, GT ;

GANAPATHI, R ;

BAUER, L ;

MURTHY, S ;

ADELSTEIN, D ;

WEICK, J ;

GIBSON, V ;

MCLAIN, D ;

SERGI, J ;

BUKOWSKI, RM .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (08) :1122-1127

[4]

BUDD GT, 1996, P AN M AM SOC CLIN, V15, P532

[5]

CAPIZZI RL, 1993, CANCER, V72, P3495, DOI 10.1002/1097-0142(19931201)72:11+<3495::AID-CNCR2820721617>3.0.CO

[6]

2-B

[7] RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY FOR ANEMIC CANCER-PATIENTS ON COMBINATION CHEMOTHERAPY [J].

CASE, DC ;

BUKOWSKI, RM ;

CAREY, RW ;

FISHKIN, EH ;

HENRY, DH ;

JACOBSON, RJ ;

JONES, SE ;

KELLER, AM ;

KUGLER, JW ;

NICHOLS, CR ;

SALMON, SE ;

SILVER, RT ;

STORNIOLO, AM ;

WAMPLER, GL ;

DOOLEY, CM ;

LARHOLT, KM ;

NELSON, RA ;

ABELS, RI .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) :801-806

[8]

CISPLATIN, 1994, CANC CHEMOTHERAPY HD, P286

[9] CYCLOPHOSPHAMIDE CYSTITIS - IDENTIFICATION OF ACROLEIN AS THE CAUSATIVE AGENT [J].

COX, PJ .

BIOCHEMICAL PHARMACOLOGY, 1979, 28 (13) :2045-2049

[10] REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].

CRAWFORD, J ;

OZER, H ;

STOLLER, R ;

JOHNSON, D ;

LYMAN, G ;

TABBARA, I ;

KRIS, M ;

GROUS, J ;

PICOZZI, V ;

RAUSCH, G ;

SMITH, R ;

GRADISHAR, W ;

YAHANDA, A ;

VINCENT, M ;

STEWART, M ;

GLASPY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170

← 1 2 3 →